Vol 86, No 5 (2015)
ARTICLES
Perinatal outcome in women with inflammatory bowel disease
DOI: 10.17772/gp/2426
Ginekol Pol 2015;86(5).
Abstract
Introduction: Inflammatory bowel disease (IBD) is a lifelong, chronic inflammatory condition of the gastrointestinal
tract. IBD morbidity rate in Europe has been steadily growing for the last six decades. Women with IBD are often diagnosed
during the childbearing years, which makes the influence of the disease on pregnancy and birth outcomes
an important clinical issue.
Objectives: The aim of the study was to estimate the influence of the IBD process among pregnant women on
maternal, fetal and neonatal parameters. Material and methods: A retrospective analysis of data on patients suffering
from IBD, diagnosed before pregnancy, who were admitted to the Department of Perinatology and Gynecology,
Polish Mother’s Memorial Hospital Research Institute for delivery between 2009-2013, was conducted. IBD was
diagnosed in 10 cases. The control group consisted of 10 healthy, pregnant women near delivery.
Results: IBD activity status at conception in women receiving continuous mesalazine treatment does not correlate
with gestational age, birth weight, Apgar score or maternal platelet count at delivery in comparison to controls.
IBD patients under mesalazine management had lower: i) maternal body mass index and platelet count, ii) neonatal
birth weight and Apgar score as compared to controls. However, no impact of IBD on the frequency of congenital
anomalies was noted.
Conclusions: To the best of our knowledge, this has been the first study conducted among pregnant women with
IBD in Poland. The analysis demonstrates that pharmacological treatment has a deteriorating influence on maternal
weight gain in pregnancy, as well as production and activity of platelets. Moreover, it diminishes fetal growth and
worsens short-term neonatal condition. Further studies with larger sample size are necessary but the rarity of this
complication limits the possibility of research.erapeutic perspectives.
Keywords: inflammatory bowel disease / mesalazine treatment / perinatal outcomes /